Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 7, 2008 - Issue 6
Submit an article Journal homepage
867
Views
44
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

Paroxetine: safety and tolerability issues

David M Marks Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA
, MD,
Min-Hyeon Park The Catholic University of Korea College of Medicine, Kangnam St. Mary's Hospital, Department of Psychiatry, Seoul 137-701, South Korea +82 2 590 2769; +82-2-6442-2789; [email protected]
, MD,
Byung-Joo Ham Hallym University Medical Center, Hangang Sacred Heart Hospital, Department of Psychiatry, Seoul, South Korea
, MD,
Changsu Han Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA; 4Korea University, Department of Psychiatry, Seoul, South Korea
, MD,
Ashwin A Patkar Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA
, MD,
Prakash S Masand Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA
, MD &
Chi-Un Pae Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA; The Catholic University of Korea College of Medicine, Kangnam St. Mary's Hospital, Department of Psychiatry, Seoul 137-701, South Korea +82 2 590 2769; +82-2-6442-2789; [email protected]
, MD show all
Pages 783-794 | Published online: 04 Nov 2008

Bibliography

  • Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001;7(1):25-47
  • Pae CU, Patkar AA. Paroxetine: current status in psychiatry. Expert Rev Neurother 2007;7(2):107-20
  • Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs 2004;18(6):355-64; discussion 365-6
  • Heydorn WE. Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders. Expert Opin Investig Drugs 1999;8(4):417-41
  • Greb WH, Brett MA, Buscher G, et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr Scand Suppl 1989;350:99-101
  • Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62(4):655-703
  • Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75
  • Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998;55(1):85-120
  • Einarson A, Koren G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Can Fam Physician 2006;52:593-4
  • Owens MJ, Krulewicz S, Simon JS, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology 2008. [Epub ahead of print]
  • Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40(2):288-95
  • Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987;93(2):193-200
  • Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992;6(Suppl 4):59-64
  • Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25(1):119-42
  • Bell C, Wilson S, Rich A, et al. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology (Berl) 2003;166(2):102-10
  • Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial prim care companion. J Clin Psychiatry 2005;7(2):53-60
  • Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193(2):352-60
  • Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002;63(7):577-84
  • Dunner DL, Lipschitz A, Pitts CD, Davies JT. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther 2005;27(12):1901-11
  • Gutman DA, Owens MJ. Serotonin and norepinephrine transporter binding profile of SSRIs. Essent Psychopharmacol 2006;7(1):35-41
  • Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42(6):757-63
  • Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16(5):356-62
  • Stahl MM, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997;53(3-4):163-9
  • Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006;20(8):665-72
  • Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006;67(Suppl 4):27-30
  • Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(Suppl 2):10-2
  • Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 2004;65(3):405-13
  • Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19(1):67-85
  • Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders – III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(3 Suppl B):S55-87
  • Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17(2):65-9
  • GlaxoSmithKline. Paxil; 2006
  • GlaxoSmithKline. Paxil CR; 2006
  • EPIP083. Available from: http://ctr.gsk.co.uk/Summary/paroxetine/epip083part2.pdf [Access date 14 June 2006]
  • Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21(3):221-2
  • Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007;29(5):918-26
  • Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279(8):609-10
  • Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55(7):503-8
  • Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7
  • Einarson A, Pistelli A, Desantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165(6):749-52
  • Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80(1):18-27
  • Sanz EJ, De-Las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365(9458):482-7
  • Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160(2):173-6
  • Cohen L. The FDA advisory on paroxetine. ObGyn News 2006;41:10
  • Patkar AA, Bilal L, Masand PS. Pharmacotherapy of depression in pregnancy. Ann Clin Psychiatry 2004;16:87-100
  • Wagner KD. Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacol Bull 2003;37(Suppl 1):167-75
  • Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001;40(7):762-72
  • Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004;43(11):1387-96
  • Wagner BM, Wong SA, Jobes DA. Mental health professionals' determinations of adolescent suicide attempts. Suicide Life Threat Behav 2002;32(3):284-300
  • FDA. Statement on recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committees. 16 September 2004. Available from: http://www.fda.gov/bbs/topics/news/2004/new01116.html [Last accessed 15 May 2008]
  • FDA. Clinical review: relationship between antidepressant drugs and suicidality in adults. Rockville, Md, Food and Drug Administration, Center for Drug Evaluation and Research, 17 Nov 2006. Available from: http://wwwfdagov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDApdf [Last accessed 15 May 2008]
  • Hammad TA. Review and evaluation of clinical data. Washington, DC, Food and Drug Administration, 16 August 2004. Available from: http://wwwfdagov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Reviewpdf
  • Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164(9):1356-63
  • Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297(15):1683-96
  • Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum Psychopharmacol 2003;18(3):185-90
  • Reynolds CF III. Paroxetine treatment of depression in late life. Psychopharmacol Bull 2003;37(Suppl 1):123-34
  • Ghose K. Tolerance and side-effects of paroxetine in elderly depressed patients. Arch Gerontol Geriatr 1997;24(1):35-45
  • Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001;18(5):355-68
  • Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13(2):100-08
  • Mittmann N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997;46(3):191-217
  • HPG2-250/85. Available from: http://ctr.gsk.co.uk/summary/paroxetine/studylist.asp
  • Dunner DL, Cohn JB, Walshe T III, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53(Suppl):57-60
  • Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 1989;350:132-4
  • Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995;119(3):277-81
  • Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999;60(Suppl 20):16-20
  • Trivedi MH, Pigotti TA, Perera P, et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65(10):1356-64
  • Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002;63(5):396-402
  • Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):S34-9
  • Budman CL, Sherling M, Bruun RD. Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 1995;34(3):263-4
  • Rahme E, Dasgupta K, Turecki G, et al. Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study. J Clin Psychiatry 2008;69(3):349-57
  • EMEA. Available from: http://eudravigilance.emea.europa.eu/human/index.asp
  • GlaxoSmithKline. A post-marketing surveillance to monitor the safety of Seroxat (paroxetine hydrochloride) administered in Korean subjects according to the prescribing information. Study No: 29060/516
  • GlaxoSmithKline. Study No: BRL29060A/104228
  • GlaxoSmithKline. Study No.: 29060/650
  • Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 2007;68(Suppl 8):26-34
  • Papakostas GI. Limitations of contemporary antidepressants: tolerability. J Clin Psychiatry 2007;68(Suppl 10):11-7
  • Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306(6879):683-7
  • Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001;16(3):169-78
  • Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158(6):906-12
  • Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(Suppl 1):19-26
  • Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005;66(1):94-9
  • Mazeh D, Shahal B, Aviv A, et al. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. Int Clin Psychopharmacol 2007;22(6):371-5
  • Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19(6):387-96
  • Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002;10(5):541-50
  • Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61(9):656-63
  • Keene MS, Eaddy MT, Mauch RP, et al. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs). Curr Med Res Opin 2005;21(10):1651-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.